Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)
November 25, 2020 11:48 AM EST
Outsourcing
Coronavirus

Af­ter Ko­dak de­ba­cle, US lends $1.1B to a syn­thet­ic bi­ol­o­gy com­pa­ny and their big Covid-19, mR­NA plans

Jason Mast

Editor

In mid-Au­gust, as Ko­dak’s $765 mil­lion gov­ern­ment-backed push in­to drug man­u­fac­tur­ing slow­ly fell apart in na­tion­al head­lines, Gink­go Bioworks CEO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times